Is $9.7B too big a price for The Medicines Company? Novartis itself seems to think so

10th December 2019 Uncategorised 0

When Novartis unveiled its $9.7 billion buyout of The Medicines Company a few days ago, several industry watchers suggested the price was too high. Turns out, Novartis’ own number-crunching “could not justify $85 per share” for the PCSK9 drug developer, SEC documents show—but even so, the company at one point offered as much as $90.

More: Is .7B too big a price for The Medicines Company? Novartis itself seems to think so
Source: fierce